{"nctId":"NCT01593787","briefTitle":"Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction","startDateStruct":{"date":"2012-05"},"conditions":["Hypertension With Renal Dysfunction"],"count":32,"armGroups":[{"label":"LCZ696 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696"]},{"label":"LCZ696 200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696"]},{"label":"LCZ696 400 mg","type":"EXPERIMENTAL","interventionNames":["Drug: LCZ696"]}],"interventions":[{"name":"LCZ696","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Renal findings: Hypertensive patients with renal dysfunction and stable renal condition at least 4 weeks before screening visit.\n* Satisfy office msSBP ≥140 mmHg and \\<180 mmHg at baseline.\n\nExclusion Criteria:\n\n* Patients show msDBP ≥110 mmHg and/or msSBP ≥180 mmHg.\n* History of angioedema, drug-related or otherwise, as reported by the patient.\n* Any other following renal disorder:\n* Patients show eGFR \\< 15mL/min/1.73m\\^2\n* Patients on dialysis\n* Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death)","description":"Percentage of patients with total adverse events, serious adverse events and death were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"27.8","spread":null},{"groupId":"OG003","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8","description":"Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.71","spread":"12.314"},{"groupId":"OG001","value":"-27.19","spread":"10.557"},{"groupId":"OG002","value":"-17.79","spread":"10.701"},{"groupId":"OG003","value":"-20.50","spread":"11.329"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.17","spread":"4.690"},{"groupId":"OG001","value":"-9.94","spread":"7.557"},{"groupId":"OG002","value":"-7.99","spread":"6.385"},{"groupId":"OG003","value":"-8.32","spread":"6.308"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Successful BP Control at Week 8","description":"A successful BP control was defined as msSBP \\<130 mmHg and msDBP \\<80 mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"37.5","spread":null},{"groupId":"OG002","value":"5.6","spread":null},{"groupId":"OG003","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving SBP Control at Week 8","description":"SBP control was defined as msSBP \\<130 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"44.4","spread":null},{"groupId":"OG003","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving DBP Control at Week 8","description":"DBP control was defined as msDBP \\<80 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"62.5","spread":null},{"groupId":"OG002","value":"27.8","spread":null},{"groupId":"OG003","value":"46.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Successful Response Rate in msSBP at Week 8","description":"Successful response rate was defined as msSBP \\<130 mmHg or a reduction of ≥20 mmHg from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"59.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Successful Response Rate in msDBP at Week 8","description":"Successful response rate was defined as msDBP \\<80 mmHg or a reduction of ≥10 mmHg from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"87.5","spread":null},{"groupId":"OG002","value":"61.1","spread":null},{"groupId":"OG003","value":"71.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["NASOPHARYNGITIS","SUPRAVENTRICULAR EXTRASYSTOLES","DYSPEPSIA","TOOTHACHE","ARTHRALGIA"]}}}